Table 3.
Multivariate analyses of disease-free survival.
| Variable | Category | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR | 95% CI | P-value | |||
| Pre-NAC status | cT stage | T1-2 vs. T3-4 | 1.057 | 0.458-2.441 | 0.896 |
| cN stage | N0 vs. N1-3 | 10.190 | 1.367–75.974 | 0.024 | |
| ER status | Positive vs. Negative | 1.556 | 0.508–4.761 | 0.439 | |
| PR status | Positive vs. Negative | 2.346 | 1.043–5.275 | 0.039 | |
| Shannon index for c-MYC CNV | Low vs. High | 2.342 | 1.059–5.182 | 0.036 | |
| Ki-67 index | <20% vs. ≥20% | 1.162 | 0.424–3.187 | 0.771 | |
| Post-NAC status | ypT stage | T1 vs. T2–4 | 1.515 | 0.687–3.344 | 0.303 |
| ypN stage | N0 vs. N1-3 | 2.638 | 1.067–6.519 | 0.036 | |
| Miller-Payne grade | Grade 3–4 vs. 1–2 | 1.019 | 0.489–2.123 | 0.960 | |
| ER status | Positive vs. Negative | 3.400 | 1.695–6.822 | 0.001 | |
| PR status | Positive vs. Negative | 1.905 | 0.763–4.757 | 0.167 | |
| Shannon index for c-MYC CNV | Low vs. High | 2.122 | 1.071–4.204 | 0.031 | |
| Ki-67 index | <20% vs. ≥20% | 1.025 | 0.348–3.020 | 0.965 | |
HR, hazard ratio; CI, confidence interval; NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; CNV, copy number variation.